Differing performance of two assays for the measurement of anti‐Mullerian hormone in premenopausal women: A cross‐sectional study

Bell, Robin J.; Skiba, Marina; Sikaris, Ken; Liu, Angela; Islam, Rakibul M; Davis, Susan Ruth

doi:10.1111/cen.14458

Cited by 7 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include the use of multiple different assays from a variety of manufacturers, reflecting the evolution of AMH measurement across nearly two decades of research. These assays differ in their sensitivities, limits of detection, and limits of quantification and are not interchangeable ( Iliodromiti et al , 2017 ; Bungum et al , 2018 ; Bell et al , 2021b ). This limited direct between-study comparisons of the number of women with undetectable AMH as well as comparisons of prognostic models.…”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

Self Cite

View full text Add to dashboard Cite

BACKGROUND The early onset of menopause is associated with increased risks of cardiovascular disease and osteoporosis. As a woman’s circulating anti-Müllerian hormone (AMH) concentration reflects the number of follicles remaining in the ovary and declines towards the menopause, serum AMH may be of value in the early diagnosis and prediction of age at menopause. OBJECTIVE AND RATIONALE This systematic review was undertaken to determine whether there is evidence to support the use of AMH alone, or in conjunction with other markers, to diagnose menopause, to predict menopause, or to predict and/or diagnose premature ovarian insufficiency (POI). SEARCH METHODS A systematic literature search for publications reporting on AMH in relation to menopause or POI was conducted in PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials up to 31 May 2022. Data were extracted and synthesized using the Synthesis Without Meta-analysis for diagnosis of menopause, prediction of menopause, prediction of menopause with a single/repeat measurement of AMH, validation of prediction models, short-term prediction in perimenopausal women, and diagnosis and prediction of POI. Risk-of-bias was evaluated using the Tool to Assess Risk of Bias in Cohort Studies protocol and studies at high risk of bias were excluded. OUTCOMES A total of 3207 studies were identified, and 41, including 28 858 women, were deemed relevant and included. Of the three studies that assessed AMH for the diagnosis of menopause, one showed that undetectable AMH had equivalent diagnostic accuracy to elevated FSH (>22.3 mIU/ml). No study assessed whether AMH could be used to shorten the 12 months of amenorrhoea required for a formal diagnosis of menopause. Studies assessing AMH with the onset of menopause (27 publications [n = 23 835 women]) generally indicated that lower age-specific AMH concentrations are associated with an earlier age at menopause. However, AMH alone could not be used to predict age at menopause with precision (with estimates and CIs ranging from 2 to 12 years for women aged <40 years). The predictive value of AMH increased with age, as the interval of prediction (time to menopause) shortened. There was evidence that undetectable, or extremely low AMH, may aid early diagnosis of POI in young women with a family history of POI, and women presenting with primary or secondary amenorrhoea (11 studies [n = 4537]). WIDER IMPLICATIONS The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved accuracy for the prediction of imminent menopause, but diagnostic use for individual patients has not been rigorously examined. Prediction of age at menopause remains imprecise when it is not imminent, although the finding of very low AMH values in young women is both of clinical value in indicating an increased risk of developing POI and may facilitate timely diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

Self Cite

View full text Add to dashboard Cite

show abstract

“…This difference may in part be due to the use of older, less sensitive assays in previous studies, which can result in higher values at lower concentrations. 34 We also compared patterns of AMH over time with those in the published literature. A study that measured AMH in healthy term girls (n = 13 girls) at 2 days and 1 month of age showed an increase in AMH over this time period.…”

Section: Discussionmentioning

confidence: 99%

“…This difference may in part be due to the use of older, less sensitive assays in previous studies, which can result in higher values at lower concentrations. 34…”

Section: Discussionmentioning

confidence: 99%

Early Life Anti-Müllerian Hormone Trajectories in Infant Girls

et al. 2023

View full text Add to dashboard Cite

Background: Minipuberty is a period of increased reproductive axis activity in infancy, but the importance of this period is not well understood, especially in girls. Previous studies reported a peak in hormone concentrations at 3 to 4 months old. Our objective is to describe anti-Müllerian hormone (AMH) trajectories in the context of other minipuberty factors among healthy infant girls using longitudinal measures of AMH. Methods: The Infant Feeding and Early Development study is a longitudinal cohort study of healthy infants, recruited from hospitals in the Philadelphia area during 2010 to 2013. We measured AMH in 153 girls who contributed 1366 serum samples across 11 study visits over 36 weeks. We also measured follicle stimulating hormone (FSH), estradiol, and ovarian characteristics. We used latent class mixed effects models to cluster trajectories of AMH concentration with age. Using linear mixed models, we estimated FSH and ovarian characteristic trajectories separately by AMH cluster. Results: We classified infants into four clusters that represent patterns of AMH that were high and decreasing (decreasing), had a peak around 12 weeks or 20 weeks (early peak and middle peak), or were consistently low (low). Infants in these clusters differed in their FSH trajectories, timing of estradiol production, and ovarian characteristics. Conclusions:The AMH clusters identified suggest variation in the timing and the magnitude of the minipuberty response in infant girls. The decreasing and low clusters have not been described previously and should be further evaluated to determine whether they represent an opportunity for the early identification of later reproductive conditions.

show abstract

“…These kits, i.e., ultrasensitive AMH and picoAMH ELISA, can detect very low blood AMH levels. Although these kits use the same antibodies and calibrators, picoAMH ELISA can cover the lower range of the standard curve 73–78 . Good correlations of assay values have been found between these new kits and conventional kits 79–82 (Table 1).…”

Section: Follicle Growth and Its Prediction In Patients With Poimentioning

confidence: 92%

Follicle development and its prediction in patients with primary ovarian insufficiency: Possible treatments and markers to maximize the ability to conceive with residual follicles

Osuka,

Kasahara,

Iyoshi

et al. 2023

Reprod Medicine & Biology

View full text Add to dashboard Cite

BackgroundPrimary ovarian insufficiency (POI) is characterized by the development of hypergonadotropic hypogonadism before 40 years of age and leads to intractable infertility. Although in vitro fertilization and embryo transfer with donated eggs enables pregnancy, not a few patients desire pregnancy using their oocytes. However, follicular development is rare and unpredictable in patients with POI. Thus, there is a need for treatments that promote the development of residual follicles and methods to accurately predict infrequent ovulation.MethodsThis review discusses the effects of various treatments for obtaining eggs from POI patients. Furthermore, this study focused a potential marker for predicting follicular growth in patients with POI.Main FindingsDifferent treatments such as hormone‐replacement therapy, dehydroepiandrosterone supplementation, platelet‐rich plasma injection, and in vitro activation have shown varying degrees of effectiveness in retrieving oocytes from patients with POI. To predict follicle development in the cycle, elevated serum estradiol and reduced follicle‐stimulating hormone (FSH) levels are important. However, these markers are not always reliable under continuous estradiol‐replacement therapy. As a novel marker for predicting follicle growth, serum anti‐Müllerian hormone (AMH) levels, measured using the picoAMH enzyme‐linked immunosorbent assay, were found to predict follicle growth in patients and the cycle.ConclusionThis review highlights the challenges and available interventions for achieving pregnancy using a patient's oocytes in cases of POI. We believe that a combination of currently available treatments and prediction methods is the best strategy to enable patients with POI to conceive using their own eggs. Although AMH levels may predict follicle growth, further research is necessary to improve the chances of successful follicular development and conception in patients with POI.

show abstract

Differing performance of two assays for the measurement of anti‐Mullerian hormone in premenopausal women: A cross‐sectional study

Cited by 7 publications

References 25 publications

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Early Life Anti-Müllerian Hormone Trajectories in Infant Girls

Follicle development and its prediction in patients with primary ovarian insufficiency: Possible treatments and markers to maximize the ability to conceive with residual follicles

Contact Info

Product

Resources

About